Abstract
Changes in voice and speech are thought to involve 75–90 % of people with PD, but the impact of PD progression on voice/speech parameters is not well defined. In this study, we assessed voice/speech symptoms in 48 parkinsonian patients staging <3 on the modified Hoehn and Yahr scale and 37 healthy subjects using the Robertson dysarthria profile (a clinical–perceptual method exploring all components potentially involved in speech difficulties), the Voice handicap index (a validated measure of the impact of voice symptoms on quality of life) and the speech evaluation parameter contained in the Unified Parkinson’s Disease Rating Scale part III (UPDRS-III). Accuracy and metric properties of the Robertson dysarthria profile were also measured. On Robertson dysarthria profile, all parkinsonian patients yielded lower scores than healthy control subjects. Differently, the Voice Handicap Index and the speech evaluation parameter contained in the UPDRS-III could detect speech/voice disturbances in 10 and 75 % of PD patients, respectively. Validation procedure in Parkinson’s disease patients showed that the Robertson dysarthria profile has acceptable reliability, satisfactory internal consistency and scaling assumptions, lack of floor and ceiling effects, and partial correlations with UPDRS-III and Voice Handicap Index. We concluded that speech/voice disturbances are widely identified by the Robertson dysarthria profile in early parkinsonian patients, even when the disturbances do not carry a significant level of disability. Robertson dysarthria profile may be a valuable tool to detect speech/voice disturbances in Parkinson’s disease.
Similar content being viewed by others
References
Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211
Bohnen NI, Cham R (2006) Postural control, gait, and dopamine functions in parkinsonian movement disorders. Clin Geriatr Med 22:797–812
Darley FL, Aronson AE, Brown JR (1969) Clusters of deviant speech dimensions in he dysarthrias. J Speech Lang Hear Res 12:462
Darley FL, Aronson AE, Brown JR (1969) Differential diagnostic patterns of dysarthria. J Speech Hear Res 12:246–269
Sapir S, Ramig L, Fox C (2008) Speech and swallowing disorders in Parkinson disease. Curr Opin Otolaryngol Head Neck Surg 16:205–210
Ramig LO, Fox C, Sapir S (2008) Speech treatment for Parkinson’s disease. Expert Rev Neurother 8:297–309
Ho AK, Iansek HR, Marigliani C, Bradshawa JL, Gates S (1999) Speech impairment in a large sample of patients with Parkinson’s disease. Behav Neurol 11:131–137
Logemann JA, Fisher HB, Boshes B, Blonsky ER (1978) Frequency and co-occurrence of vocal tract dysfunction in the speech of a large sample of parkinsonian patiens. J Speech Heart Disord 43:47–57
Muller J, Wenning GK, Verny M, McKee A, Chaudury KR, Jellinger K, Poewe W, Litvan I (2001) Progression of Dysarthria and dysphagia in post-mortem confirmed parkinsonian disorders. Arch Neurol 58:259–264
Rusz J, Cmejla R, Ruzickova H, Ruzicka E (2011) Quantitative acoustic measurements for characterization of speech and voice disorders in early untreated Parkinson’s disease. J Acoust Soc Am 129:350–367
Stewart C, Winfield L, Hunt A, Bressman SB, Fahn S, Blitzer A, Brin MF (1995) Speech dysfunction in early Parkinson’s disease. Mov Disord 10:562–565
Skodda S, Rinsche H, Schlegel U (2009) Progression of dysprosody in Parkinson’s disease over time—a longitudinal study. Mov Disord 24:716–722
Midi I, Dogan M, Koseoglu M, Can G, Sehitoglu MA, Gunal DI (2008) Voice abnormalities and their relation with motor dysfunction in Parkinson’s disease. Acta Neurol Scand 117:26–34
Rusz J, Cmejla R, Ruzickova H et al (2011) Acoustic assessment of voice and speech disorders in Parkinson’s disease through quick vocal test. Mov Disord 26(10):1951–1952
Goberman AM, Coelho C (2002) Acoustic analysis of Parkinsonian speech I: speech characteristics and l-Dopa therapy. NeuroRehabilitation 17:237–246
Robertson SJ, Thomson F (1987) Working with dysarthric clients: a practical guide to therapy for dysarthria. Communication Skill Builders, Tucson
Fussi FC (2010) Profilo di valutazione della disartria. Adattamento italiano del test di Robertson, raccolta di dati normativi e linee di intervento. Omega Edizioni, Torino
Albanese A, Sorbo FD, Comella C et al (2013) Dystonia rating scales: critique and recommendations. Mov Disord 28:874–883
Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427–442
Jacobson B, Johnson A, Grywalski C et al (1997) The Voice Handicap Index (VHI): development and validation. Am J Speech-Lang Pathol 6:66–69
Schindler A, Ottaviani F, Mozzanica F et al (2010) Cross-cultural adaptation and validation of the Voice Handicap Index Into Italian. J Voice 24:708–714
Fahn S, Elton RL, Members of the UPDRS Development Committee (1987) Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson’s disease, vol 2. Macmillan Health Care Information, Florham Park, pp 153–164
Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson’s disease. Arch Neurol 56:33–39
Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25:2649–2653
Martinez-Martin P, Chaudhuri KR, Rojo-Abuin JM, Rodriguez-Blazquez C, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, Garretto N, Gershanik O, Kurtis MM, Martinez-Castrillo JC, Mendoza-Rodriguez A, Moore HP, Rodriguez-Violante M, Singer C, Tilley BC, Huang J, Stebbins GT, Goetz CG (2015) Assessing the non-motor symptoms of Parkinson’s disease: MDS-UPDRS and NMS Scale. Eur J Neurol 22(1):37–43
Hays RD, Anderson R, Revicki D (1993) Psychometric considerations in evaluating health-related quality of life measures. Qual Life Res 2:441–449
Nunnally JC, Bernstein IH (1994) Psychometric theory, 3rd edn. McGraw-Hill, New York
Fayers PM, Machin D (2000) Quality of life. Assessment, analysis and interpretation. Wiley, Chichester
Scientific Advisory Committee of the Medical Outcomes Trust (2002) Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res 11:193–205
Skodda S, Flasskamp A, Schlegel U (2011) Instability of syllable repetition as a marker of disease progression in Parkinson’s disease: a longitudinal study. Mov Disord 26(1):59–64
Gamboa J, Jimenez-Jimenez J, Nieto A et al (1997) Acoustic voice analysis in patients with Parkinson’s disease treated with dopaminergic drugs. J Voice 11:314–320
Skodda S, Grönheit W, Schlegel U (2012) Impairment of vowel articulation as a possible marker of disease progression in Parkinson’s disease. PLoS ONE 7:e32132
Skodda S, Visser W, Schlegel U (2011) Gender related patterns of dysprosody in Parkinson’s disease and correlation between speech variables and motor symptoms. J Voice 25:76–82
Skodda S, Visser W, Schlege U (2010) Short- and long-term dopaminergic effects on dysarthria in early Parkinson’s disease. J Neural Transm 117:197–205
Rusz J, Mejla RC, Ruzickova H et al (2013) Evaluation of speech impairment in early stages of Parkinson’s disease: a prospective study with the role of pharmacotherapy. J Neural Transm 120:319–329
Tykalová T, Rusz J, Čmejla R, Klempíř J, Růžičková H, Roth J, Růžička (2015) Effect of dopaminergic medication on speech dysfluency in Parkinson’s disease: a longitudinal study. J Neural Transm 122:1135–1142
Johansson L, Möller S, Olofsson K et al (2014) Word-level intelligibility after caudal zona incerta stimulation for Parkinson’s disease. Acta Neurol Scand 130:27–33
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
No funding has been available for study other than that of the author’s institution.
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Defazio, G., Guerrieri, M., Liuzzi, D. et al. Assessment of voice and speech symptoms in early Parkinson’s disease by the Robertson dysarthria profile. Neurol Sci 37, 443–449 (2016). https://doi.org/10.1007/s10072-015-2422-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-015-2422-8